Artificial intelligence workplan to guide use of AI in medicines regulation
  Published on December 19, 2023
© EMA 2023

Following the European artificial intelligence act, EMA and HMA have proposed a workplan from 2024 to 2028 to balance the risk-benefits of AI in drug development. The workplan addresses 4 critical AI dimensions: policies, tools, training and experiments. As part of pharmaceutical data intelligence, AI is rapidly and profoundly moving into each field of medicines discovery and development.

Scroll to Top